» Articles » PMID: 33530627

Understanding Host Immunity and the Gut Microbiota Inspires the New Development of Vaccines and Adjuvants

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2021 Feb 3
PMID 33530627
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinations improve the mortality and morbidity rates associated with several infections through the generation of antigen-specific immune responses. Adjuvants are often used together with vaccines to improve immunogenicity. However, the immune responses induced by most on-going vaccines and adjuvants approved for human use vary in individuals; this is a limitation that must be overcome to improve vaccine efficacy. Several reports have indicated that the symbiotic bacteria, particularly the gut microbiota, impact vaccine-mediated antigen-specific immune responses and promote the induction of nonspecific responses via the "training" of innate immune cells. Therefore, the interaction between gut microbiota and innate immune cells should be considered to ensure the optimal immunogenicity of vaccines and adjuvants. In this review, we first introduce the current knowledge on the immunological mechanisms of vaccines and adjuvants. Subsequently, we discuss how the gut microbiota influences immunity and highlight the relationship between gut microbes and trained innate immunity, vaccines, and adjuvants. Understanding these complex interactions will provide insights into novel vaccine approaches centered on the gut microbiota.

Citing Articles

Probiotic effects of Lactobacillus reuteri and Pediococcus pentosaceus on growth performance, blood biochemistry, and antibody response in broiler chickens.

Melese K, Alemu T, Desalegn A Braz J Microbiol. 2025; .

PMID: 40053288 DOI: 10.1007/s42770-024-01593-7.


Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.

Zhang T, Lv Y, Zhao Y, Yang J, Qian B, Zhu Y Immun Inflamm Dis. 2023; 11(11):e1082.

PMID: 38018604 PMC: 10664826. DOI: 10.1002/iid3.1082.


The intestinal microbiota and improving the efficacy of COVID-19 vaccinations.

Chen J, Vitetta L, Henson J, Hall S J Funct Foods. 2021; 87:104850.

PMID: 34777578 PMC: 8578005. DOI: 10.1016/j.jff.2021.104850.


Probiotics as Adjuvants in Vaccine Strategy: Is There More Room for Improvement?.

Peroni D, Morelli L Vaccines (Basel). 2021; 9(8).

PMID: 34451936 PMC: 8402414. DOI: 10.3390/vaccines9080811.

References
1.
Kim Y, Sakamoto K, Seo S, Pickard J, Gillilland 3rd M, Pudlo N . Neonatal acquisition of species protects against colonization by bacterial pathogens. Science. 2017; 356(6335):315-319. PMC: 6082366. DOI: 10.1126/science.aag2029. View

2.
Datta S, Sabet M, Nguyen K, Valdez P, Gonzalez-Navajas J, Islam S . Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A. 2010; 107(23):10638-43. PMC: 2890829. DOI: 10.1073/pnas.1002348107. View

3.
Wu B, Yang Y, Xu X, Wang W . Effects of Bifidobacterium supplementation on intestinal microbiota composition and the immune response in healthy infants. World J Pediatr. 2015; 12(2):177-82. DOI: 10.1007/s12519-015-0025-3. View

4.
van Riet E, Ainai A, Suzuki T, Hasegawa H . Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine. 2012; 30(40):5893-900. DOI: 10.1016/j.vaccine.2012.04.109. View

5.
Sulis G, Roggi A, Matteelli A, Raviglione M . Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014070. PMC: 4235436. DOI: 10.4084/MJHID.2014.070. View